1. Home
  2. NWBI vs LQDA Comparison

NWBI vs LQDA Comparison

Compare NWBI & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NWBI
  • LQDA
  • Stock Information
  • Founded
  • NWBI 1896
  • LQDA 2004
  • Country
  • NWBI United States
  • LQDA United States
  • Employees
  • NWBI N/A
  • LQDA N/A
  • Industry
  • NWBI Major Banks
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NWBI Finance
  • LQDA Health Care
  • Exchange
  • NWBI Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • NWBI 1.7B
  • LQDA 1.7B
  • IPO Year
  • NWBI N/A
  • LQDA 2018
  • Fundamental
  • Price
  • NWBI $11.49
  • LQDA $19.49
  • Analyst Decision
  • NWBI Hold
  • LQDA Strong Buy
  • Analyst Count
  • NWBI 1
  • LQDA 9
  • Target Price
  • NWBI $15.00
  • LQDA $27.67
  • AVG Volume (30 Days)
  • NWBI 1.2M
  • LQDA 2.5M
  • Earning Date
  • NWBI 07-29-2025
  • LQDA 08-12-2025
  • Dividend Yield
  • NWBI 6.87%
  • LQDA N/A
  • EPS Growth
  • NWBI 38.60
  • LQDA N/A
  • EPS
  • NWBI 1.11
  • LQDA N/A
  • Revenue
  • NWBI $561,855,000.00
  • LQDA $14,144,000.00
  • Revenue This Year
  • NWBI $7.42
  • LQDA $190.73
  • Revenue Next Year
  • NWBI $11.81
  • LQDA $421.01
  • P/E Ratio
  • NWBI $10.45
  • LQDA N/A
  • Revenue Growth
  • NWBI 14.22
  • LQDA N/A
  • 52 Week Low
  • NWBI $10.75
  • LQDA $8.26
  • 52 Week High
  • NWBI $15.42
  • LQDA $20.57
  • Technical
  • Relative Strength Index (RSI)
  • NWBI 23.67
  • LQDA 61.18
  • Support Level
  • NWBI $11.61
  • LQDA $16.82
  • Resistance Level
  • NWBI $11.75
  • LQDA $20.57
  • Average True Range (ATR)
  • NWBI 0.27
  • LQDA 1.24
  • MACD
  • NWBI -0.14
  • LQDA 0.08
  • Stochastic Oscillator
  • NWBI 2.79
  • LQDA 72.94

About NWBI Northwest Bancshares Inc.

Northwest Bancshares Inc is a stockholding company for Northwest Bank. Northwest Bank is a stock savings bank and a community-oriented financial institution offering personal and commercial banking business solutions, investment management, trust services, and insurance products. It also offers consumer finance loans through a wholly-owned subsidiary. The bank's loan portfolio segment consists of personal banking and business banking loans. Personal banking includes residential mortgages, home equity loans, and other consumer loans. Business banking loans consist of commercial real estate loans and commercial loans. Net interest income is the company's primary contributor to revenue.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: